Multitargeted therapies for multiple myeloma |
| |
Authors: | Pedram Kharaziha Sophia Ceder Claire Sanchez Theocharis Panaretakis |
| |
Affiliation: | Department of Oncology-Pathology; Cancer Centre Karolinska; Karolinska Institutet; Stockholm, Sweden |
| |
Abstract: | Multiple myeloma (MM) comprises 1% of all malignancies and 10% of all hematological malignancies. MM is a malignancy of plasma cells in the bone marrow where complex and dynamic interactions with the bone marrow microenvironment lead to tumor progression, skeletal destruction and angiogenesis. Despite the discovery of several novel treatments against MM, including the proteasome inhibitor bortezomib, it is considered to be an incurable disease with an average 4–5 years overall survival. |
| |
Keywords: | sorafenib multiple myeloma 5T33MM autophagy bone marrow stroma ABT737 cell death tyrosine kinase inhibitor |
|